Navigation Links
Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma

CHICAGO and REGENSBURG - June 21, 2007 - “In anaplastic astrocytoma, AP 12009 as a monotherapy is actually clearly superior to temozolomide,” Prof. Albert Wong, M.D., Stanford University, California, U.S.A. commented on the international Phase IIb study with the TGF-beta 2-inhibitor AP 12009, under development by Antisense Pharma. Prof. Wong discussed the results of the study in the poster discussion session on central nervous system tumors at the 43rd Annual Meeting of the American Society of Clincal Oncology (ASCO) in Chicago, USA, this month.

The Phase IIb study AP 12009-G004 is an open-label, randomized, actively-controlled, parallel-group dose-finding study to evaluate the efficacy and safety of two doses of AP 12009 in adult patients with recurrent high-grade glioma. Efficacy endpoints were tumor response assessed by central blinded MRI reading and survival. At 29 international clinical centers 134 evaluable patients (39 with anaplastic astrocytoma, AA, WHO grade III and 95 with glioblastoma, GBM, WHO grade IV) have been randomized to three arms: AP 12009 10 ?M, AP 12009 80 ?M and chemotherapy (Temozolomide or PCV) as a control. AP 12009 was administered intratumorally via one catheter as continuous high-flow microperfusion over a 7-day period every other week for up to 6 months on an outpatient treatment basis (1, 2). Post-study follow-up for survival, long-term tumor response, and safety is still ongoing. Analysis of the core phase for AA patients is completed.

Tumor response was assessed according to Macdonald criteria. The response rate for AP 12009 10 ?M in anaplastic astrocytoma patients steadily increased in the course of 14 months, whereas in the chemotherapy treatment arm a transient peak of the response rate at 6 months was not sustainable and decreased to zero at 14 months. Response rates were higher in the AP 12009 10 ?M group compared to the AP 12009 80 ?M group. The
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Lorus Therapeutics Announces Scientific Presentations for Lead Antisense and siRNA Drug Candidates at International Cancer Conference
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:5/23/2013)... Mass. , May 23, 2013  Hologic, ... HOLX ), a leading developer, manufacturer and supplier ... products, with an emphasis on serving the healthcare ... large-scale observational study in a U.S. clinical practice ... technology (breast tomosynthesis) with conventional 2D mammography alone ...
(Date:5/23/2013)... , May 23, 2013  Ameritox, the ... selected by Progressive Medical, Inc. to become part ... help clients manage pharmacy costs and improve the ... Medical, a leading pharmacy benefit manager in the ... overall medication compliance and pain management strategy for ...
(Date:5/23/2013)... AVIV, Israel , May 23, 2013 ... BrainTech Israel 2013 , Israel,s ... place on October 14 th -15 th in ... nd most innovative city in the world by the ... "Start-up Nation." BrainTech Israel 2013 will showcase the ...
Breaking Medicine Technology:First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... 2012 Berg Pharma, a Boston based pharmaceutical company ... cancer cell metabolism at the 103rd Annual AACR meeting.  ... the meeting that dealt with endothelial cell biology relative ... priming of cancer therapy, synergy of BPM 31510, Berg,s ...
... Inc. (NYSE: ZMH ; SIX: ZMH) announced today ... be broadcast live over the Internet on Thursday, April 26, ... the quarterly results will be made available at 7:00 a.m. ... The live audio webcast can be accessed via Zimmer,s ...
Cached Medicine Technology:Berg Pharma Presents Key Findings in Cancer Systems Biology and Mitochondrial Metabolism at AACR Meeting 2Berg Pharma Presents Key Findings in Cancer Systems Biology and Mitochondrial Metabolism at AACR Meeting 3Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2012 Results 2
(Date:5/24/2013)... 24, 2013 The SunglassFIX Photo ... sunglasses all while learning how to make their ... Contestants only need to upload pictures of ... "like" The Sunglass Fix on Facebook in order ... the largest lens replacement online store . ...
(Date:5/24/2013)... aortic valve implantation (TAVI) is effective and safe in ... results from a multicentre Asian registry reported at EuroPCR ... a treatment option for selected patients with symptomatic severe ... North American or European centres," Paul Chiam, senior consultant ... conference. He explained that it is unknown whether the ...
(Date:5/24/2013)... In a coup that surely made other Palm ... the Estetica Institute of the Palm Beaches performed eye surgeries ... morning show, “The Mo & Sally Morning Show.” The DJ’s ... with the results, giving Dr. DeLange and the team at ... Gardens, very valuable free publicity. , Dr. DeLange, the owner ...
(Date:5/24/2013)... Atlanta, GA (PRWEB) May 24, 2013 CBT ... of Sales. Gonter joins the web-based retail automotive industry news ... sales. , “I’m excited to join a group that’s ... a perfect example of how online video content is on ... career in the motorcycle business and segued into advertising at ...
(Date:5/24/2013)... The Institute for Integrative Nutrition , ... it has donated $10,000 to the Cleveland Courage Fund ... Cleveland, Ohio. , “When the news came out on Monday, ... Berry and her daughter had escaped from a Cleveland home ... and horrified,” said Integrative Nutrition Founder, Director, and Primary Teacher ...
Breaking Medicine News(10 mins):Health News:Break the Sunglass Mold – Reuse 'Em, Don’t Toss 'Em then Enter the SunglassFIX Photo Contest to Win 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:Dr. Greg DeLange of the Estetica Institute Recently Performed Eye Surgery on Both Members of Popular Morning Radio Team 2Health News:Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund 2
... a competitive application process, Michele D. Kipke, PhD, Vice ... Hospital Los Angeles, was awarded a $420,000 grant which ... Autism Treatment Network (ATN) as an ATN Center of ... Speaks, which is North America,s largest autism science and ...
... hemorrhagic fever in humans, has no known cure or vaccine. ... scientists has uncovered a family of small molecules which appear ... inhibit its entry into human cells. The results are ... and are now online. Previous studies have shown ...
... discovered that cells lining the blood vessels secrete molecules ... invading other tissues, a finding that could lead to ... professor in the MIT-Harvard Division of Health Sciences and ... a patient,s tumor could shrink a tumor or prevent ...
... to research conducted at the Oregon National Primate Research Center ... that oral contraceptives cause weight gain appears to be false. ... appear in next month,s edition of the journal Human ... reveal that contraceptives and the possibility that they may cause ...
... WEDNESDAY, Jan. 19 (HealthDay News) -- Many U.S. transplant ... trying to develop new safeguards that would protect and ... one-third of transplant surgeons in the nation "overreacted" to ... contracted HIV after receiving organs from a single donor ...
... a gene that is mutated in one in three patients ... of a frequently mutated gene will provide new insights into ... critical in the continued effort to improve treatment for renal ... to be mutated in 88 cases out of 257 clear ...
Cached Medicine News:Health News:Children's Hospital Los Angeles joins Autism Treatment Network 2Health News:Small molecules may prevent ebola infection 2Health News:MIT scientists discover cancer-fighting role for cells 2Health News:MIT scientists discover cancer-fighting role for cells 3Health News:MIT scientists discover cancer-fighting role for cells 4Health News:Do birth control pills cause weight gain? New research says no 2Health News:Research provides new kidney cancer clues 2Health News:Research provides new kidney cancer clues 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: